Posted on July 31st, 2010 by Health News
SynCo Bio Partners today announced an extension of its successful collaboration with Versartis, Inc. following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus (T2DM) patients with monthly dosing of VRS-859. This news comes less than 12 months since the parties entered into a strategic partnership to manufacture Versartis’ lead [...]
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Bio-Path Holdings, Inc.,, a biotechnology company with drug development operations in Houston, Texas, announced today that the first patient has been dosed in a Phase I study of its cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), in patients with Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) or Myelodysplastic Syndrome [...]
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Curaxis Pharmaceutical Corp. is pleased to announce the completion of its reverse merger with Auto Search Cars, Inc.. The effective date of the Merger is July 29, 2010.
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often [...]
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were [...]
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company’s unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson’s disease psychosis (PDP).
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Despite a sluggish year, health care investors can look forward to growing emerging markets and a possible change in the U.S. political climate, Forbes reports. “Health care has not had a banner year in 2010 as the sector’s stocks have underperformed the market on account of reform in the United States and financial problems in [...]
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave® were published online in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration…
No Comments »
Filed under: Pharmacy News
Posted on July 31st, 2010 by Health News
The latest court case exploring the link between Wyeth Pharmaceuticals’ hormonal replacement drug Prempro and breast cancer started Tuesday in Philadelphia, the Philadelphia Inquirer reports…
No Comments »
Filed under: Pharmacy News
